SCHEMBL5162822

SCHEMBL5162822

O=C(OSc1ccccn1)OSc1ccccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.50
EHMT1 Q9H9B1 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
ALDH1A1 P00352 6/20 0.47
LMNA P02545 2/20 0.46
KMT2A Q03164 2/20 0.44
MAPT P10636 1/20 0.44
MEN1 O00255 1/20 0.44
PKM P14618 1/20 0.44
POLB P06746 2/20 0.42
RAB9A P51151 4/20 0.42
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
SMN1; SMN2 Q16637 5/20 0.41
HPGD P15428 4/20 0.41
HSD17B10 Q99714 3/20 0.41
NPC1 O15118 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALOX15 P16050 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL670302 0.86 ALDH1A1 (0.50) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL10347772 0.85 EHMT2 (0.47) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL28950323 0.85 LMNA (0.47) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL1607376 0.80 LMNA (0.55) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL28254695 0.78 LMNA (0.52) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL1360606 0.76 EHMT2 (0.61) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL535803 0.76 LMNA (0.50) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL7664866 0.74 EHMT2 (0.58) EHMT2EHMT1APOBEC3GALDH1A1LMNA
Hydrochloric Acid SCHEMBL28708511 0.74 EHMT2 (0.58) EHMT2EHMT1APOBEC3GALDH1A1LMNA
SCHEMBL10226670 0.73 EHMT2 (0.52) EHMT2EHMT1APOBEC3GALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1575929-B1 THE METHOD FOR PRODUCTION OF SEMI-FINISHED PRODUCTS USEFUL IN SYNTHESIS OF PACLITAXEL AGROPHARM S A (PL) 2007-03-21 EP disclosed
EP-1575929-A1 THE METHOD FOR PRODUCTION OF SEMI-FINISHED PRODUCTS USEFUL IN SYNTHESIS OF PACLITAXEL Agropharm S.A. (PL) 2005-09-21 EP disclosed
WO-2004056790-A1 THE METHOD FOR PRODUCTION OF SEMI-FINISHED PRODUCTS USEFUL IN SYNTHESIS OF PACLITAXEL AGROPHARM S.A. (PL) 2004-07-08 WO disclosed
EP-0842174-B1 HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA PF MEDICAMENT (FR) 2001-10-04 EP disclosed
US-5767256-A REACTING HYDROXYL GROUP-CONTAINING ACCEPTOR WITH DONOR SELECTED FROM O-PYRANOSYL AND O-FURANOSYL GLYCOSIDES HAVING PYRIDINE-CONTAINING LEAVING GROUPS HANESSIAN STEPHEN (CA) 1998-06-16 US disclosed
EP-0842174-A1 HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA PIERRE FABRE MEDICAMENT (FR) 1998-05-20 EP disclosed
WO-1997005134-A1 HETEROCYCLIC COMPOUNDS FOR TREATING MYOCARDIAL ISCHAEMIA PIERRE FABRE MEDICAMENT (FR) 1997-02-13 WO disclosed
US-5436240-A Schizophrenia, Parkinson's disease, depression or hypotensive agents using tricyclic amines THE UPJOHN COMPANY (US) 1995-07-25 US disclosed
EP-0480939-B1 HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY UPJOHN CO (US) 1995-01-25 EP disclosed
US-5273975-A Heterocyclic amines having central nervous system activity THE UPJOHN COMPANY (US) 1993-12-28 US disclosed
EP-0480939-A1 HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY. UPJOHN CO (US) 1992-04-22 EP disclosed
WO-1990015058-A1 HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY THE UPJOHN COMPANY (US) 1990-12-13 WO disclosed